![Michael Bailey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Bailey
Vorstandsvorsitzender bei
AVEO PHARMACEUTICALS, INC.
Vermögen: 467 640 $ am 31.05.2026
Profil
Michael P.
Bailey is currently President, Chief Executive Officer & Director at AVEO Pharmaceuticals, Inc. since 2010.
He is Chairman at IMV, Inc. since 2022 and Director at Verastem, Inc. starting in 2026.
Formerly, Mr. Bailey was a Member of Global Commercial Partnership Teams at Genentech, Inc., Senior Vice President-Commercial Operations at ImClone LLC from 1999 to 2008, and Chief Commercial Officer & Senior Vice President at Synta Pharmaceuticals Corp.
from 2008 to 2010.
Education includes undergraduate studies at St. Lawrence University and an MBA from Mendoza College of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VERASTEM, INC. 0,18 % | 21.05.2026 | 108 000 ( 0,18 % ) | 467 640 $ | 31.05.2026 |
Aktive Positionen von Michael Bailey
| Unternehmen | Position | Beginn |
|---|---|---|
| AVEO PHARMACEUTICALS, INC. | Vorstandsvorsitzender | 06.01.2015 |
| IMV INC. | Vorsitzender | 01.05.2022 |
| VERASTEM, INC. | Direktor/Vorstandsmitglied | 26.05.2026 |
Ehemalige bekannte Positionen von Michael Bailey
| Unternehmen | Position | Ende |
|---|---|---|
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel pharmaceutical products | Corporate Officer/Principal | 07.09.2010 |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology Develops novel therapeutic products and blood cell growth factors for the treatment of cancer | Corporate Officer/Principal | 01.08.2008 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
Ausbildung von Michael Bailey
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
60
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology Develops novel therapeutic products and blood cell growth factors for the treatment of cancer | Health Technology |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel pharmaceutical products | Health Technology |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops cancer therapeutics | Health Technology |
St. Lawrence University
 St. Lawrence University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IMV, Inc.
 IMV, Inc. BiotechnologyHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
Verastem, Inc.
 Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
Mendoza College of Business
 Mendoza College of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
